{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:22:45Z","timestamp":1791958965561,"version":"4.3.4"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T00:00:00Z","timestamp":1478044800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40257-016-0232-2","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T01:24:29Z","timestamp":1478049869000},"page":"193-213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review"],"prefix":"10.1007","volume":"18","author":[{"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Versteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,2]]},"reference":[{"issue":"5","key":"232_CR1","first-page":"519","volume":"60","author":"M Araya","year":"2015","unstructured":"Araya M, Kulthanan K, Jiamton S. Clinical characteristics and quality of life of seborrheic dermatitis patients in a tropical country. Indian J Dermatol. 2015;60(5):519.","journal-title":"Indian J Dermatol"},{"issue":"6","key":"232_CR2","first-page":"348","volume":"35","author":"T Berk","year":"2010","unstructured":"Berk T, Scheinfeld N. Seborrheic dermatitis. Pharm Ther. 2010;35(6):348.","journal-title":"Pharm Ther"},{"issue":"5","key":"232_CR3","first-page":"1","volume":"15","author":"I Stefanaki","year":"2010","unstructured":"Stefanaki I, Katsambas A. Therapeutic update on seborrheic dermatitis. Skin Ther Lett. 2010;15(5):1\u20134.","journal-title":"Skin Ther Lett"},{"issue":"1","key":"232_CR4","first-page":"125","volume":"74","author":"RA Schwartz","year":"2006","unstructured":"Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74(1):125\u201330.","journal-title":"Am Fam Physician"},{"issue":"6 Suppl","key":"232_CR5","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1067\/mjd.2003.274","volume":"48","author":"RM Halder","year":"2003","unstructured":"Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48(6 Suppl):S143\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"232_CR6","first-page":"32","volume":"4","author":"JQ Rosso Del","year":"2011","unstructured":"Del Rosso JQ. Adult seborrheic dermatitis: a status report on practical topical management. J Clin Aesthetic Dermatol. 2011;4(5):32\u20138.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"232_CR7","first-page":"CD009446","volume":"5","author":"H Kastarinen","year":"2014","unstructured":"Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkk\u00e4 J, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;5:CD009446.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"232_CR8","first-page":"2","volume":"165","author":"RJ Hay","year":"2011","unstructured":"Hay RJ. Malassezia, dandruff and seborrhoeic dermatitis: an overview. Br J Dermatol. 2011;165(Suppl 2):2\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"232_CR9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1468-3083.2004.00693.x","volume":"18","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol JEADV. 2004;18(1):13\u201326 (quiz 19\u201320).","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"4","key":"232_CR10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000247566","volume":"184","author":"JP Ortonne","year":"1992","unstructured":"Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2\u00a0% foaming gel and betamethasone dipropionate 0.05\u00a0% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatol Basel Switz. 1992;184(4):275\u201380.","journal-title":"Dermatol Basel Switz"},{"issue":"8","key":"232_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/1348-0421.12398","volume":"60","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Cho O, Saito C, Saito M, Tsuboi R, Sugita T. Comprehensive pyrosequencing analysis of the bacterial microbiota of the skin of patients with seborrheic dermatitis. Microbiol Immunol. 2016;60(8):521\u20136.","journal-title":"Microbiol Immunol."},{"key":"232_CR12","unstructured":"Johnson BA, Nunley JR. Treatment of seborrheic dermatitis. Am Fam Physician 2000;61(9):2703\u201310, 2713\u20134."},{"issue":"3","key":"232_CR13","first-page":"185","volume":"91","author":"GW Clark","year":"2015","unstructured":"Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185\u201390.","journal-title":"Am Fam Physician"},{"issue":"11","key":"232_CR14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0151-9638(07)92826-4","volume":"134","author":"L Misery","year":"2007","unstructured":"Misery L, Touboul S, Vin\u00e7ot C, Dutray S, Rolland-Jacob G, Consoli S-G, et al. Stress and seborrheic dermatitis. Ann Dermatol V\u00e9n\u00e9r\u00e9ologie. 2007;134(11):833\u20137.","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ologie"},{"issue":"2","key":"232_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000076478","volume":"208","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatol Basel Switz. 2004;208(2):89\u201393.","journal-title":"Dermatol Basel Switz"},{"issue":"4","key":"232_CR16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMcp0806464","volume":"360","author":"L Naldi","year":"2009","unstructured":"Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med. 2009;360(4):387\u201396.","journal-title":"N Engl J Med"},{"key":"232_CR17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000444682","volume":"1","author":"WK Choeng","year":"2015","unstructured":"Choeng WK, Yeung CK, Torsekar RG, Suh DH, Ungpakorn R, Widaty S, et al. Treatment of seborrhoeic dermatitis in Asia: a consensus guide. Skin Appendage Disord. 2015;1:187\u201396.","journal-title":"Skin Appendage Disord"},{"issue":"4","key":"232_CR18","first-page":"226","volume":"16","author":"P Chatzikokkinou","year":"2008","unstructured":"Chatzikokkinou P, Sotiropoulos K, Katoulis A, Luzzati R, Trevisan G. Seborrheic dermatitis\u2014an early and common skin manifestation in HIV patients. Acta Dermatovenerol Croat ADC. 2008;16(4):226\u201330.","journal-title":"Acta Dermatovenerol Croat ADC"},{"issue":"5","key":"232_CR19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/000155598443051","volume":"78","author":"B Cribier","year":"1998","unstructured":"Cribier B, Samain F, Vetter D, Heid E, Grosshans E. Systematic cutaneous examination in hepatitis C virus infected patients. Acta Derm Venereol. 1998;78(5):355\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"232_CR20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000250109","volume":"164","author":"A Barba","year":"1982","unstructured":"Barba A, Piubello W, Vantini I, Caliari S, Cocchetto R, Vallaperta P, et al. Skin lesions in chronic alcoholic pancreatitis. Dermatologica. 1982;164(5):322\u20136.","journal-title":"Dermatologica"},{"issue":"4","key":"232_CR21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2340\/0001555563335339","volume":"63","author":"E Tegner","year":"1983","unstructured":"Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol. 1983;63(4):335\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"232_CR22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1439-0507.2008.01624.x","volume":"52","author":"JC Szepietowski","year":"2009","unstructured":"Szepietowski JC, Reich A, Weso\u0142owska-Szepietowska E, Baran E, National Quality of Life in Dermatology Group. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses. 2009;52(4):357\u201363.","journal-title":"Mycoses"},{"key":"232_CR23","doi-asserted-by":"crossref","unstructured":"Elewski B. An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05\u00a0% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. Clin Dermatol 2009;27(6 Suppl):S48\u201353.","DOI":"10.1016\/j.clindermatol.2009.09.002"},{"issue":"2","key":"232_CR24","first-page":"125","volume":"8","author":"J Bikowski","year":"2009","unstructured":"Bikowski J. Facial seborrheic dermatitis: a report on current status and therapeutic horizons. J Drugs Dermatol JDD. 2009;8(2):125\u201333.","journal-title":"J Drugs Dermatol JDD"},{"issue":"Suppl 1","key":"232_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000249633","volume":"169","author":"D Berg","year":"1984","unstructured":"Berg D, Plempel M. Bifonazole, a biochemist\u2019s view. Dermatologica. 1984;169(Suppl 1):3\u20139.","journal-title":"Dermatologica"},{"issue":"6","key":"232_CR26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00128071-200405060-00006","volume":"5","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Batra R, Nicol K. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004;5(6):417\u201322.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"232_CR27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-4632.2004.02123.x","volume":"43","author":"V Baysal","year":"2004","unstructured":"Baysal V, Yildirim M, Ozcanli C, Ceyhan AM. Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality. Int J Dermatol. 2004;43(1):63\u20136.","journal-title":"Int J Dermatol"},{"issue":"2","key":"232_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00128071-200910020-00003","volume":"10","author":"BA Cook","year":"2009","unstructured":"Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol. 2009;10(2):103\u201318.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"232_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/jdv.12197","volume":"28","author":"AK Gupta","year":"2014","unstructured":"Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol JEADV. 2014;28(1):16\u201326.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"8","key":"232_CR30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1517\/14656566.5.8.1755","volume":"5","author":"AK Gupta","year":"2004","unstructured":"Gupta AK, Kogan N. Seborrhoeic dermatitis: current treatment practices. Expert Opin Pharmacother. 2004;5(8):1755\u201365.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"232_CR31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5826\/dpc.0603a04","volume":"6","author":"Z Abbas","year":"2016","unstructured":"Abbas Z, Ghodsi SZ, Abedeni R. Effect of itraconazole on the quality of life in patients with moderate to severe seborrheic dermatitis: a randomized, placebo-controlled trial. Dermatol Pract Concept. 2016;6(3):11\u20136.","journal-title":"Dermatol Pract Concept"},{"key":"232_CR32","first-page":"CD008138","volume":"5","author":"EO Okokon","year":"2015","unstructured":"Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN. Topical antifungals for seborrhoeic dermatitis. Cochrane Database Syst Rev. 2015;5:CD008138.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"232_CR33","first-page":"359","volume":"40","author":"H Wat","year":"2014","unstructured":"Wat H, Wu DC, Rao J, Goldman MP. Application of intense pulsed light in the treatment of dermatologic disease: a systematic review. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2014;40(4):359\u201377.","journal-title":"Dermatol Surg Off Publ Am Soc Dermatol Surg Al"},{"issue":"1","key":"232_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3122\/jabfm.17.1.59","volume":"17","author":"MH Ebell","year":"2004","unstructured":"Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract Am Board Fam Pract. 2004;17(1):59\u201367.","journal-title":"J Am Board Fam Pract Am Board Fam Pract"},{"issue":"5","key":"232_CR35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1046\/j.1523-1747.1998.00181.x","volume":"110","author":"SW Byeon","year":"1998","unstructured":"Byeon SW, Pelley RP, Ullrich SE, Waller TA, Bucana CD, Strickland FM. Aloe barbadensis extracts reduce the production of interleukin-10 after exposure to ultraviolet radiation. J Invest Dermatol. 1998;110(5):811\u20137.","journal-title":"J Invest Dermatol"},{"key":"232_CR36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/09546639909055904","volume":"10","author":"D Vardy","year":"1998","unstructured":"Vardy D, Cohen A, Tchetov T, Medvedovsky E, Biton A. A double-blind, placebo-controlled trial of an Aloe vera (A. barbadensis) emulsion in the treatment of seborrheic dermatitis. J Dermatol Treat 1998;10:7\u201311.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"232_CR37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2672.1995.tb05025.x","volume":"78","author":"CF Carson","year":"1995","unstructured":"Carson CF, Riley TV. Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia. J Appl Bacteriol. 1995;78(3):264\u20139.","journal-title":"J Appl Bacteriol"},{"issue":"6","key":"232_CR38","first-page":"388","volume":"9","author":"P Nenoff","year":"1996","unstructured":"Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol Off J Skin Pharmacol Soc. 1996;9(6):388\u201394.","journal-title":"Skin Pharmacol Off J Skin Pharmacol Soc"},{"issue":"5","key":"232_CR39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ptr.1862","volume":"20","author":"F Caldefie-Ch\u00e9zet","year":"2006","unstructured":"Caldefie-Ch\u00e9zet F, Fusillier C, Jarde T, Laroye H, Damez M, Vasson M-P, et al. Potential anti-inflammatory effects of Melaleuca alternifolia essential oil on human peripheral blood leukocytes. Phytother Res PTR. 2006;20(5):364\u201370.","journal-title":"Phytother Res PTR"},{"issue":"51","key":"232_CR40","first-page":"26","volume":"13","author":"RA Beheshti","year":"2014","unstructured":"Beheshti RA, Tavakoli-far B, Fallah HH, Tousi P, Shafigh N, Rahimzadeh M. Efficacy of Melaleuca alternifolia essential oil in the treatment of facial seborrheic dermatitis: a double-blind, randomized, placebo-controlled clinical trial. J Med Plants. 2014;13(51):26\u201332.","journal-title":"J Med Plants"},{"issue":"1","key":"232_CR41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0378-8741(02)00334-3","volume":"85","author":"W Toma","year":"2003","unstructured":"Toma W, Gracioso JS, Hiruma-Lima CA, Andrade FDP, Vilegas W, Souza Brito ARM. Evaluation of the analgesic and antiedematogenic activities of Quassia amara bark extract. J Ethnopharmacol. 2003;85(1):19\u201323.","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"232_CR42","first-page":"312","volume":"12","author":"C Diehl","year":"2013","unstructured":"Diehl C, Ferrari A. Efficacy of topical 4\u00a0% Quassia amara gel in facial seborrheic dermatitis: a randomized, double-blind, comparative study. J Drugs Dermatol JDD. 2013;12(3):312\u20135.","journal-title":"J Drugs Dermatol JDD"},{"issue":"2","key":"232_CR43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00128071-200102020-00008","volume":"2","author":"LJ Scott","year":"2001","unstructured":"Scott LJ, Dunn CJ, Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol. 2001;2(2):95\u2013120.","journal-title":"Am J Clin Dermatol"},{"key":"232_CR44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09546630152608339","volume":"12","author":"J Berth-Jones","year":"2001","unstructured":"Berth-Jones J, Adnitt P. Topical calcipotriol is not effective in facial seborrhoeic dermatitis. J Dermatol Treat. 2001;12:179.","journal-title":"J Dermatol Treat"},{"issue":"6 Pt 1","key":"232_CR45","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0190-9622(92)70302-V","volume":"27","author":"K Kragballe","year":"1992","unstructured":"Kragballe K. Treatment of psoriasis with calcipotriol and other vitamin D analogues. J Am Acad Dermatol. 1992;27(6 Pt 1):1001\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"232_CR46","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/09546639609086874","volume":"7","author":"T Tadaki","year":"1996","unstructured":"Tadaki T, Kato T, Tagami H. Topical active vitamin D3 analogue, 1,24-dihydroxycholecalciferol, an effective new treatment for facial seborrhoeic dermatitis. J Dermatol Treat. 1996;7:139\u201341.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"232_CR47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-4362.1995.tb04449.x","volume":"34","author":"AR Shalita","year":"1995","unstructured":"Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34(6):434\u20137.","journal-title":"Int J Dermatol"},{"issue":"3","key":"232_CR48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/09546634.2013.814754","volume":"25","author":"G Fabbrocini","year":"2014","unstructured":"Fabbrocini G, Cantelli M, Monfrecola G. Topical nicotinamide for seborrheic dermatitis: an open randomized study. J Dermatol Treat. 2014;25(3):241\u20135.","journal-title":"J Dermatol Treat"},{"issue":"1","key":"232_CR49","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jaad.2011.02.032","volume":"67","author":"KA Papp","year":"2012","unstructured":"Papp KA, Papp A, Dahmer B, Clark CS. Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1\u00a0% ointment compared with tacrolimus 0.1\u00a0% ointment in adults. J Am Acad Dermatol. 2012;67(1):e11\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"232_CR50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2340\/00015555-1532","volume":"93","author":"T-W Kim","year":"2013","unstructured":"Kim T-W, Mun J-H, Wa S-WJ, Song M, Kim H-S, Ko H-C, et al. Proactive treatment of adult facial seborrheic dermatitis with 0.1\u00a0% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-center trial. Acta Derm Venereol. 2013;93:557\u201361.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"232_CR51","doi-asserted-by":"crossref","first-page":"523","DOI":"10.5021\/ad.2015.27.5.523","volume":"27","author":"HO Kim","year":"2015","unstructured":"Kim HO, Yang YS, Ko HC, Kim GM, Cho SH, Seo YJ, et al. Maintenance therapy of facial seborrheic dermatitis with 0.1\u00a0% tacrolimus ointment. Ann Dermatol. 2015;27(5):523\u201330.","journal-title":"Ann Dermatol"},{"issue":"2","key":"232_CR52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2133.1999.02974.x","volume":"141","author":"M Grassberger","year":"1999","unstructured":"Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141(2):264\u201373.","journal-title":"Br J Dermatol"},{"issue":"8","key":"232_CR53","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archderm.142.8.1066","volume":"142","author":"A Firooz","year":"2006","unstructured":"Firooz A, Solhpour A, Gorouhi F, Daneshpazhooh M, Balighi K, Farsinejad K, et al. Pimecrolimus cream, 1\u00a0%, vs hydrocortisone acetate cream, 1\u00a0%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142(8):1066\u20137.","journal-title":"Arch Dermatol"},{"issue":"1","key":"232_CR54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2165\/11311160-000000000-00000","volume":"11","author":"MG Ozden","year":"2010","unstructured":"Ozden MG, Tekin NS, Ilter N, Ankarali H. Topical pimecrolimus 1\u00a0% cream for resistant seborrheic dermatitis of the face: an open-label study. Am J Clin Dermatol. 2010;11(1):51\u20134.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"232_CR55","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3346\/jkms.2007.22.5.868","volume":"22","author":"B-S Kim","year":"2007","unstructured":"Kim B-S, Kim S-H, Kim M-B, Oh C-K, Jang H-S, Kwon K-S. Treatment of facial seborrheic dermatitis with pimecrolimus cream 1\u00a0%: an open-label clinical study in Korean patients. J Korean Med Sci. 2007;22(5):868\u201372.","journal-title":"J Korean Med Sci"},{"issue":"5","key":"232_CR56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2133.2004.06208.x","volume":"151","author":"D Rigopoulos","year":"2004","unstructured":"Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, Katsambas A. Pimecrolimus cream 1\u00a0% vs. betamethasone 17-valerate 0.1\u00a0% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol. 2004;151(5):1071\u20135.","journal-title":"Br J Dermatol"},{"issue":"1","key":"232_CR57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/09546630802286993","volume":"20","author":"E Koc","year":"2009","unstructured":"Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1\u00a0% cream and topical ketoconazole 2\u00a0% cream in the treatment of seborrheic dermatitis. J Dermatol Treat. 2009;20(1):4\u20139.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"232_CR58","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/09546630802687349","volume":"20","author":"D Cicek","year":"2009","unstructured":"Cicek D, Kandi B, Bakar S, Turgut D. Pimecrolimus 1\u00a0% cream, methylprednisolone aceponate 0.1\u00a0% cream and metronidazole 0.75\u00a0% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatol Treat. 2009;20(6):344\u20139.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"232_CR59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2006.11.007","volume":"57","author":"EM Warshaw","year":"2007","unstructured":"Warshaw EM, Wohlhuter RJ, Liu A, Zeller SA, Wenner RA, Bowers S, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1\u00a0% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57(2):257\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"232_CR60","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1365-4362.1997.00309.x","volume":"36","author":"T Rosen","year":"1997","unstructured":"Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36(10):788\u201392.","journal-title":"Int J Dermatol"},{"issue":"3","key":"232_CR61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00044011-200222030-00003","volume":"22","author":"A Unholzer","year":"2002","unstructured":"Unholzer A, Schinzel S, Nietsch K-H, Jung GE, Korting HC. Ciclopiroxolamine cream 1\u00a0% in the treatment of seborrhoeic dermatitis: a double-blind, parallel-group comparison with ketoconazole and vehicle in a confirmatory trial. Clin Drug Invest. 2002;22(3):167\u201372.","journal-title":"Clin Drug Invest"},{"issue":"3","key":"232_CR62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000068904","volume":"206","author":"O Chosidow","year":"2003","unstructured":"Chosidow O, Maurette C, Dupuy P. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1\u00a0% cream and ketoconazole 2\u00a0% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatol Basel Switz. 2003;206(3):233\u201340.","journal-title":"Dermatol Basel Switz"},{"issue":"4","key":"232_CR63","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00403-006-0679-8","volume":"298","author":"F Liebel","year":"2006","unstructured":"Liebel F, Lyte P, Garay M, Babad J, Southall MD. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch Dermatol Res. 2006;298(4):191\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"232_CR64","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14787210.3.3.333","volume":"3","author":"AJ Carrillo-Mu\u00f1oz","year":"2005","unstructured":"Carrillo-Mu\u00f1oz AJ, Giusiano G, Ezkurra PA, Quind\u00f3s G. Sertaconazole: updated review of a topical antifungal agent. Expert Rev Anti Infect Ther. 2005;3(3):333\u201342.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"232_CR65","first-page":"895","volume":"10","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Cantrell WC. An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis. J Drugs Dermatol JDD. 2011;10(8):895\u20139.","journal-title":"J Drugs Dermatol JDD"},{"issue":"9\u201310","key":"232_CR66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1439-0507.1993.tb00776.x","volume":"36","author":"H Zienicke","year":"1993","unstructured":"Zienicke H, Korting HC, Braun-Falco O, Effendy I, Hagedorn M, K\u00fcchmeister B, et al. Comparative efficacy and safety of bifonazole 1\u00a0% cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis. Mycoses. 1993;36(9\u201310):325\u201331.","journal-title":"Mycoses"},{"issue":"6","key":"232_CR67","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1439-0507.1989.tb02249.x","volume":"32","author":"J Faergemann","year":"1989","unstructured":"Faergemann J. Treatment of seborrhoeic dermatitis with bifonazole. Mycoses. 1989;32(6):309\u201311.","journal-title":"Mycoses"},{"key":"232_CR68","unstructured":"Pfizer. Diflucan tablets (Fluconazole) Label Information [Internet]. 2011 [cited 2012 May 30]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019949s055,019950s059,020090s038lbl.pdf ."},{"issue":"2","key":"232_CR69","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-4362.1994.tb01546.x","volume":"33","author":"D Rigopoulos","year":"1994","unstructured":"Rigopoulos D, Katsambas A, Antoniou C, Theocharis S, Stratigos J. Facial seborrheic dermatitis treated with fluconazole 2\u00a0% shampoo. Int J Dermatol. 1994;33(2):136\u20137.","journal-title":"Int J Dermatol"},{"issue":"1B","key":"232_CR70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(83)90508-9","volume":"74","author":"J Cutsem Van","year":"1983","unstructured":"Van Cutsem J. The antifungal activity of ketoconazole. Am J Med. 1983;74(1B):9\u201315.","journal-title":"Am J Med"},{"issue":"2 Pt 1","key":"232_CR71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0190-9622(91)70192-5","volume":"25","author":"J Cutsem Van","year":"1991","unstructured":"Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PA. The antiinflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. J Am Acad Dermatol. 1991;25(2 Pt 1):257\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"232_CR72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2133.1987.tb05815.x","volume":"116","author":"CA Green","year":"1987","unstructured":"Green CA, Farr PM, Shuster S. Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole. Br J Dermatol. 1987;116(2):217\u201321.","journal-title":"Br J Dermatol"},{"key":"232_CR73","unstructured":"Elocon (mometasone furoate) Ointment, 0.1\u00a0% for topical use [Internet]. FDA US Food Drug Adm. 2013 [cited 2016 May 26]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019543s024lbl.pdf ."},{"key":"232_CR74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/09546639209088705","volume":"3","author":"R Medansky","year":"1992","unstructured":"Medansky R, Lepaw M, Shavin J, Zimmerman E, Jones M, Peets E, et al. Mometasone furoate cream 0.1\u00a0% vs. hydrocortisone cream 1\u00a0% in the treatment of seborrheic dermatitis. J Dermatol Treat. 1992;3:125\u20138.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"232_CR75","first-page":"887","volume":"48","author":"N Kurita","year":"1984","unstructured":"Kurita N, Funabashi M. Growth-inhibitory effect on fungi of alkali cations and monovalent inorganic anions and antagonism among different alkali cations. Agric Biol Chem. 1984;48(4):887\u201393.","journal-title":"Agric Biol Chem"},{"issue":"6","key":"232_CR76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1021\/cn500038f","volume":"5","author":"A Nassar","year":"2014","unstructured":"Nassar A, Azab AN. Effects of lithium on inflammation. ACS Chem Neurosci. 2014;5(6):451\u20138.","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"232_CR77","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1046\/j.1365-2133.2003.05328.x","volume":"148","author":"B Dreno","year":"2003","unstructured":"Dreno B, Chosidow O, Revuz J, Moyse D, STUDY INVESTIGATOR GROUP. Lithium gluconate 8\u00a0% vs ketoconazole 2\u00a0% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br J Dermatol. 2003;148(6):1230\u20136.","journal-title":"Br J Dermatol"},{"issue":"6512","key":"232_CR78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/bmj.292.6512.28","volume":"292","author":"J Boyle","year":"1986","unstructured":"Boyle J, Burton JL, Faergemann J. Use of topical lithium succinate for seborrhoeic dermatitis. Br Med J Clin Res Ed. 1986;292(6512):28.","journal-title":"Br Med J Clin Res Ed"},{"issue":"5","key":"232_CR79","first-page":"15","volume":"7","author":"T Schlesinger","year":"2014","unstructured":"Schlesinger T, Rowland Powell C. Efficacy and safety of a low molecular weight hyaluronic acid topical gel in the treatment of facial seborrheic dermatitis final report. J Clin Aesthetic Dermatol. 2014;7(5):15\u20138.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"4","key":"232_CR80","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/0378-6323.26745","volume":"72","author":"AH Siadat","year":"2006","unstructured":"Siadat AH, Iraji F, Shahmoradi Z, Enshaieh S, Taheri A. The efficacy of 1\u00a0% metronidazole gel in facial seborrheic dermatitis: a double blind study. Indian J Dermatol Venereol Leprol. 2006;72(4):266\u20139.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"232_CR81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1468-3083.2006.01927.x","volume":"21","author":"D Seckin","year":"2007","unstructured":"Seckin D, Gurbuz O, Akin O. Metronidazole 0.75\u00a0% gel vs. ketoconazole 2\u00a0% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol JEADV. 2007;21(3):345\u201350.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"8","key":"232_CR82","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1046\/j.1365-4362.2003.01981.x","volume":"42","author":"R Koca","year":"2003","unstructured":"Koca R, Altinyazar HC, E\u015ft\u00fcrk E. Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int J Dermatol. 2003;42(8):632\u20135.","journal-title":"Int J Dermatol"},{"issue":"5","key":"232_CR83","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1468-3083.2006.01923.x","volume":"21","author":"AP Moraes de","year":"2007","unstructured":"de Moraes AP, de Arruda EAG, Vitoriano MAV, de Moraes Filho MO, Bezerra FAF, de Magalh\u00e3es Holanda E, et al. An open-label efficacy pilot study with pimecrolimus cream 1\u00a0% in adults with facial seborrhoeic dermatitis infected with HIV. J Eur Acad Dermatol Venereol JEADV. 2007;21(5):596\u2013601.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"5","key":"232_CR84","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2230.1997.tb01071.x","volume":"22","author":"JA Langtry","year":"1997","unstructured":"Langtry JA, Rowland Payne CM, Staughton RC, Stewart JC, Horrobin DF. Topical lithium succinate ointment (Efalith) in the treatment of AIDS-related seborrhoeic dermatitis. Clin Exp Dermatol. 1997;22(5):216\u20139.","journal-title":"Clin Exp Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-016-0232-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T09:01:30Z","timestamp":1718874090000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-016-0232-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,2]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1007\/s40257-016-0232-2","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,2]]}}}